Send to

Choose Destination
Am J Clin Oncol. 1982 Feb;5(1):65-8.

Adjuvant immunotherapy (BCG) in stage D prostate cancer.


Thirty-three patients with advanced prostate cancer were prospectively randomized to receive either Bacillus Calmette-Guerin (BCG) adjuvant immunotherapy plus conventional therapy or conventional therapy alone. Conventional therapy consisted of estrogens or observation. There was a statistically significantly (p less than 0.05) longer survival in the 16 BCG-treated patients (42 weeks) than in the 17 control patients (29 weeks).

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center